This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

EVT 201

Evotec AG

Drug Names(s): EVT 201

Description: EVT 201 is a novel partial positive allosteric modulator of the GABA-A receptor complex which is being developed as a treatment for insomnia. As a partial agonist, EVT 201 has a lower level of GABA-A potentiation, which the company hopes will results in a better side effect profile.

Deal Structure: EVT 201 was originally developed at Roche where it completed a Phase I clinical trial. Evotec has since in-licensed the compound.

In October 2010, Evotec entered into a license and collaboration agreement with Zhejiang Jingxin Pharmaceutical for EVT 201. The agreement grants Jingxin Pharma exclusive rights to develop and market the drug candidate in China. In return, Evotec will receive a small upfront payment, together with commercial milestones and significant royalties. Evotec will have the right to reference clinical data produced by Jingxin Pharma to support potential further development of EVT 201 in other territories.

Partners: Roche Holding AG Zheijiang JingXin Pharmaceutical Co., Ltd.


EVT 201 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug